What Is The Leading Driver Behind Elevated Rates Of Obesity And Heart Disease Fuel Expansion Of The Type 2 Diabetes Market Market Expansion in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Type 2 Diabetes Industry Market Size Be by 2025?
The overall scope of the Type 2 Diabetes therapeutic area has experienced considerable expansion lately, with its valuation set to increase from $48.14 billion in the year 2024 to $51.47 billion the following year, reflecting a compound annual growth rate (CAGR) of 6.9%, a surge primarily fueled by shifts in lifestyle and eating habits, the increasing demographic of older individuals, advancements in medicinal treatments, and various public health campaigns.

What's the Long-Term Growth Forecast for the Type 2 Diabetes Market Size Through 2029?
Anticipated to experience substantial expansion in the coming years, the market dedicated to managing type 2 diabetes is projected to a valuation of $71.31 billion by the year 2029, driven by an annual compound growth rate (CAGR) calculated at 8.5%; this upward trajectory is fundamentally supported by the worldwide surge in diabetes cases, the increasing adoption of customized medical treatments, ongoing technological innovation, and evolving healthcare regulations, while key developments shaping this sector involve the rise of digital well-being platforms and remote medical consultations, a greater focus on proactive disease prevention and detection, the integration of artificial intelligence and machine learning capabilities, and the growing relevance of metabolic surgical procedures.

View the full report here:
https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

What Are the Key Growth Drivers Fueling the Type 2 Diabetes Market Expansion?
The escalating prevalence of both obesity and cardiovascular ailments is anticipated to serve as a primary catalyst for expanding the market related to type 2 diabetes in the times ahead. Obesity, defined as an unhealthy accumulation of surplus body fat, shares a mutual risk pathway with heart disease, which encompasses various conditions impacting cardiac function and vascular structures. Specifically, being overweight significantly heightens the likelihood of developing insulin resistance, ultimately resulting in elevated blood glucose levels characteristic of type 2 diabetes. Conversely, persistent high blood sugar negatively impacts the delicate nerves and blood vessels governing the heart and circulatory system, thereby precipitating heart disease. To illustrate this widespread issue, the World Health Organization, an organization headquartered in Switzerland, announced in March 2024 that roughly one in every eight individuals across the globe was dealing with obesity; this statistic included an estimated 2.5 billion adults aged 18 and over classified as overweight, with 890 million of those individuals meeting the criteria for obesity, and among the adult demographic, 43 percent were categorized as overweight while 16 percent were obese; furthermore, 37 million children under five years old were reported as overweight, underscoring the fact that the surge in both obesity and heart conditions directly fuels the expansion of the type 2 diabetes market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

What Are the Key Trends Driving Type 2 Diabetes Market Growth?
Leading corporations within the type 2 diabetes sector are focused on creating novel therapeutic options like Mounjaro, intending to elevate both the safety profile and overall efficacy standards experienced by individuals afflicted with diabetes. This pioneering medication, Mounjaro, seeks to offer advancements in how effectively, safely, or conveniently diabetes can be managed when contrasted with previously available pharmacological interventions. Developments in pharmaceutical research for diabetes are concentrating on achieving superior glycemic regulation, lessening adverse effects, and tackling concomitant health issues. Specifically, in May of 2022, the United States Food and Drug Administration, a regulatory body of the US government, granted clearance to Eli Lilly and Co., a US pharmaceutical entity, for the Mounjaro (tripeptide) injectable solution, designed to optimize blood sugar management in adult type 2 diabetes patients when used alongside prescribed diet and exercise regimens. Tirzepatide represents a significant advancement in therapy for type 2 diabetes, functioning as a novel agent with dual mechanisms, delivered via a weekly injection, which simultaneously acts upon two key appetite-regulating hormones: glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP); GLP-1 functions to boost insulin secretion while concurrently lowering glucagon output, whereas GIP contributes by enhancing insulin release. Consequently, tirzepatide emerges as a highly encouraging therapeutic avenue for those living with type 2 diabetes, including patients whose conditions have not responded adequately to previous treatment modalities.

How Is the Type 2 Diabetes Market Segmented?
The type 2 diabetesmarket covered in this report is segmented -

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists; Thiazolidinediones; Alpha-Glucosidase Inhibitors; Sulfonylureas And Other Insulin Secretagogues; Biguanides; SodiumGlucose Cotransporter 2 Inhibitors; Other Drug Classes
2) By Application: Glycemic Control; Cardiovascular Safety; Hypoglycemia Avoidance; Other Applications
3) By End-User: Children; Adults

Subsegments:
1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin
2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide; Semaglutide; Dulaglutide; Exenatide
3) By Thiazolidinediones: Pioglitazone; Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol
5) By Sulfonylureas And Other Insulin Secretagogues: Glimepiride; Glipizide; Glyburide
6) By Biguanides: Metformin
7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin
8) By Other Drug Classes: Amylin Analogues; Bile Acid Sequestrants; Dopamine Agonists

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13050&type=smp

Which Companies Are Leading the Charge in Type 2 Diabetes Market Innovation?
Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Novartis AG, AstraZeneca PLC, Abbott Laboratories, Sanofi SA, Medtronic PLC, Takeda Pharmaceutical Company, GlaxoSmithKline plc., Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Dexcom Inc., Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Byram Healthcare, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health.

Which Regions Are Leading the Global Type 2 Diabetes Market in Revenue?
North America was the largest region in the type 2 diabetes market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in type 2 diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13050

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.